Gene symbol
|
Literature data
|
Validation results
|
---|
References
|
n
|
Survival endpoint
|
Prognostic significance of high expression
|
HR (95%CI)
|
Log-rank P value
|
Datasets
|
Cut off
|
---|
KLK7
|
[20]
|
45
|
OS
|
Good
|
2.65 (1.27–5.53)†
|
0.0095
|
GSE17275
|
Upper 25%
|
| | | | |
3.60 (1.48–8.80)†
|
0.0049
|
GSE19234
|
Upper 25%
|
| | | | |
1.93 (1.40–2.65)†
|
< 0.0001
|
TCGA
|
Upper 25%
|
MITF
|
[29]
|
200
|
OS
|
Poor
|
1.43 (1.09–1.87)†
|
0.0104
|
TCGA
|
Upper 50%
|
| | | | |
3.46 (1.42–8.42)†
|
0.0063
|
GSE19234
|
Upper 50%
|
| | | | |
3.33 (1.18–9.41)†
|
0.0230
|
GSE98394
|
Upper 50%
|
KIF20A
|
[30]
|
61
|
RFS
|
Poor
|
2.17 (1.12–4.20)†
|
0.0218
|
GSE22155
|
Upper 25%
|
| | | | |
2.56 (1.20–5.47)†
|
0.0151
|
GSE50509
|
Upper 25%
|
| | | | |
3.21 (1.26–8.20)†
|
0.0147
|
GSE98394
|
Upper 25%
|
| | | | |
2.44 (1.02–5.83)†
|
0.0454
|
GSE19234
|
Upper 25%
|
CTHRC1
|
[31]
|
35
|
OS
|
Poor
|
3.41 (1.31–8.89)†
|
0.0122
|
GSE98394
|
Upper 25%
|
TFAP2A
|
[32]
|
Nearly 600
|
DSS
|
Poor
|
1.59 (1.03–2.47)‡
|
0.0379
|
GSE65904
|
Upper 25%
|
ATF2
|
[33]
|
544
|
OS
|
Poor
|
3.05 (1.56–5.97)†
|
0.0012
|
GSE22155
|
Upper 25%
|
NCOA3
|
[34]
|
343
|
RFS and DSS
|
Poor
|
1.79 (1.17–2.74)‡
|
0.0071
|
GSE65904
|
Upper 25%
|
BCL2
|
[35]
|
339
|
OS
|
Good
|
0.21 (0.04–0.97)†
|
0.0458
|
GSE22155
|
Upper 25%
|
BIRC5
|
[36]
|
50
|
DFS and OS
|
Poor
|
3.73 (1.44–9.67)†
|
0.0068
|
GSE98394
|
Upper 25%
|
MCAM
|
[37]
|
76
|
OS
|
Poor
|
4.66 (1.78–12.18)†
|
0.0017
|
GSE19234
|
Upper 25%
|
PLAT
|
[38]
|
214
|
DMFI and OS
|
Poor
|
2.24 (1.16–4.34)†
|
0.0164
|
GSE22155
|
Upper 25%
|
| | | | |
3.88 (1.47–10.24)†
|
0.0063
|
GSE98394
|
Upper 25%
|
NOS2
|
[39]
|
132
|
DSS and OS
|
Poor
|
1.41 (1.07–1.85)†
|
0.0131
|
TCGA
|
Upper 50%
|
CDKN1B
|
[40]
|
383
|
DSS and OS
|
Poor
|
0.48 (0.24–0.95)†
|
0.0341
|
GSE22155
|
Upper 25%
|
| | | | |
0.69 (0.50–0.95)†
|
0.0235
|
TCGA
|
Upper 25%
|
BCL6
|
[41]
|
88
|
6-year OS
|
Poor
|
0.57 (0.40–0.80)†
|
0.0011
|
TCGA
|
Upper 25%
|
FXYD5
|
[42]
|
115
|
OS
|
Poor
|
3.10 (1.24–7.76)†
|
0.0159
|
GSE19234
|
Upper 25%
|
DDIT3
|
[43]
|
106
|
OS
|
Good
|
5.74 (2.18–15.13)†
|
0.0004
|
GSE98394
|
Upper 25%
|
MCAT
|
[44]
|
1270
|
DFI and OS
|
Poor
|
5.75 (1.26–26.10)†
|
0.0236
|
GSE22155
|
Upper 25%
|
| | | | |
4.51 (1.72–11.82)†
|
0.0021
|
GSE98394
|
Upper 25%
|
CTNNB1
|
[45]
|
202
|
DSS
|
Good
|
1.55 (1.02–2.37)‡
|
0.0412
|
GSE65904
|
Upper 25%
|
| | | | |
1.75 (1.15–2.67)‡
|
0.0088
|
GSE65904
|
Upper 25%
|
AKT1
|
[46]
|
222
|
5-year DSS or OS
|
Poor
|
6.41 (2.39–17.23)†
|
0.0002
|
GSE98394
|
Upper 25%
|
| | | | |
1.53 (1.13–2.06)†
|
0.0056
|
TCGA
|
Upper 25%
|
RUNX3
|
[47]
|
421
|
5-year OS
|
Good
|
3.75 (1.36–10.33)†
|
0.0107
|
GSE50509
|
Upper 25%
|
| | |
5-year DSS
| |
1.81 (1.18–2.76)‡
|
0.0062
|
GSE65904
|
Upper 25%
|
BBC3
|
[48]
|
158
|
5-year DSS or OS
|
Poor
|
3.62 (1.38–9.52)†
|
0.0092
|
GSE98394
|
Upper 25%
|
MMP2
|
[49]
|
157
|
DSS and RFS
|
Poor
|
1.41 (1.06–1.89)‡
|
0.0197
|
TCGA
|
Upper 50%
|
SPP1
|
[50]
|
345
|
RFS
|
Poor
|
9.42 (3.46–25.67)†
|
< 0.0001
|
GSE98394
|
Upper 25%
|
TNC
|
[51]
|
98
|
DFS
|
Poor
|
1.54 (1.01–2.34)‡
|
0.0434
|
GSE65904
|
Upper 25%
|
CCNA2
|
[52]
|
245
|
RFS
|
Poor
|
2.23 (1.02–4.88)†
|
0.0437
|
GSE50509
|
Upper 25%
|
RGS1
|
[53]
|
40
|
DSS
|
Poor
|
2.74 (1.03–7.24)†
|
0.0425
|
GSE98394
|
Upper 25%
|
| | | | |
3.24 (1.31–8.00)†
|
0.0110
|
GSE19234
|
Upper 25%
|
| | | | |
2.66 (1.07–6.65)†
|
0.0357
|
GSE19234
|
Upper 25%
|
SPARC
|
[54]
|
112
|
DFS
|
Poor
|
2.78 (1.21–6.34)†
|
0.0154
|
GSE50509
|
Upper 25%
|
CXCR4
|
[55]
|
71
|
DFS and OS
|
Poor
|
0.70 (0.51–0.97)†
|
0.0315
|
TCGA
|
Upper 25%
|
RBM3
|
[56]
|
246
|
OS
|
Good
|
NS
|
NS
|
–
|
–
|
EPAS1
|
[57]
|
46
|
DSS
|
Poor
|
3.51 (1.56–7.91)†
|
0.0024
|
GSE50509
|
Upper 25%
|
- NS not significance, RFS recurrence-free survival, DFS disease-specific survival, DFI disease-free interval, DMFI distant metastasis-free interval
- †,‡HR (95%CI) and Log-rank P value of overall survival (OS) and disease-specific survival (DSS)